Comparing Human Albumin Versus Hydroxyethylstarch in Renal Transplant Recipients

Plasma Volume Expansion for Optimum Renal Transplant Surgery: Albumin Versus Starch

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03306914

Enrollment

120

Registered

2017-10-11

Start date

2017-10-15

Completion date

2019-02-01

Last updated

2020-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia Morbidity

Brief summary

In this study we try to review the possible effects when using modern hydroxyethylstarch solutions 6 % versus albumin 5% during living donor renal transplantation.

Interventions

OTHERAlbumin resuscitation

Albumin 5% is used as the intra-operative colloid

OTHERHydroxyethylstarch resuscitation

Hydroxyethyl starch 6% is used as the intra-operative colloid

DRUGAlbumin 5%

Infusion of Albumin 5% intra-operatively

DRUGHydroxyethylstarch 6%

Infusion of Hydroxyethylstarch 6% intra-operatively

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SUPPORTIVE_CARE

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Inclusion criteria

* end stage renal disease, for living donor renal transplantation

Exclusion criteria

* severe cardiac or hepatic dysfunction, re-transplantation, coagulopathy

Design outcomes

Primary

Measure	Time frame	Description
Occurrence of complications	7 days	Increased creatinine and/or need for dialysis

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026